R&D expense · 2011–2025
Supernus Pharmaceuticals R&D expense
$106M−2.4% · FY2025
Supernus Pharmaceuticals (SUPN) reported $106M in R&D expense for fiscal 2025, −2.4% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $106M | −2.4% | Open → |
| FY20242024-12-31 | $109M | +18.8% | Open → |
| FY20232023-12-31 | $91.6M | +22.9% | Open → |
| FY20222022-12-31 | $74.6M | −17.6% | Open → |
| FY20212021-12-31 | $90.5M | +19.1% | Open → |
| FY20202020-12-31 | $76.0M | +9.9% | Open → |
| FY20192019-12-31 | $69.1M | −22.5% | Open → |
| FY20182018-12-31 | $89.2M | +79.9% | Open → |
| FY20172017-12-31 | $49.6M | +15.9% | Open → |
| FY20162016-12-31 | $42.8M | +46.9% | Open → |
| FY20152015-12-31 | $29.1M | +48.8% | Open → |
| FY20142014-12-31 | $19.6M | +13.6% | Open → |
| FY20132013-12-31 | $17.2M | −26.7% | Open → |
| FY20122012-12-31 | $23.5M | −23.2% | Open → |
| FY20112011-12-31 | $30.6M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +9.3%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Supernus Pharmaceuticals R&D expense |url=https://companiesranked.com/en/company/supernus-pharmaceuticals/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Supernus Pharmaceuticals R&D expense. CompaniesRanked. https://companiesranked.com/en/company/supernus-pharmaceuticals/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-supernus-pharmaceuticals-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Supernus Pharmaceuticals R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/supernus-pharmaceuticals/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001356576-26-000011 · March 2, 2026
{{cite web |title=Supernus Pharmaceuticals R&D expense — 10-K (0001356576-26-000011) |url=https://www.sec.gov/Archives/edgar/data/1356576/000135657626000011/supn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.